Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1

In a regulatory filing, Zydus Cadila said "it has received permission to initiate the phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process".

from Moneycontrol Business News https://ift.tt/2L3Ak6L